Hamid Emamekhoo
Oncology | Hematology Oncology | Hematology
1040 Division St
Mauston, WI 53948
Mauston, WI 53948
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 06, 2026
HSR26-206: The Future of Oncology Research: Replacing Case Report Forms With mCODE-Aligned Electronic Health Record Data for Clinical Trial Data Curation (Alliance).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
HSR26-206: The Future of Oncology Research: Replacing Case Report Forms With mCODE-Aligned Electronic Health Record Data for Clinical Trial Data Curation (Alliance).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 20, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.
Journal: Clinical genitourinary cancer
Published: December 02, 2025
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.
Journal: Investigational new drugs
Published: November 14, 2025
Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence-driven oncology care.
Journal: Cancer
Published: August 27, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Journal: Investigational new drugs
Published: August 11, 2025
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.
Journal: Cell reports. Medicine
Published: July 17, 2025
Last Updated: 09/26/2026